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Abstract
Background: RNA activation (RNAa) is a newly discovered mechanism of gene activation triggered by small double-
stranded RNAs termed ‘small activating RNAs’ (saRNAs). Thus far, RNAa has only been demonstrated in human cells and is
unclear whether it is conserved in other mammals.
Methodology/Principal Findings: In the present study, we evaluated RNAa in cells derived from four mammalian species
including nonhuman primates (African green monkey and chimpanzee), mouse, and rat. Previously, we identified saRNAs
leading to the activation of E-cadherin, p21, and VEGF in human cells. As the targeted sequences are highly conserved in
primates, transfection of each human saRNA into African green monkey (COS1) and chimpanzee (WES) cells also resulted in
induction of the intended gene. Additional saRNAs targeting clinically relevant genes including p53, PAR4, WT1, RB1, p27,
NKX3-1, VDR, IL2, and pS2 were also designed and transfected into COS1 and WES cells. Of the nine genes, p53, PAR4, WT1,
and NKX3-1 were induced by their corresponding saRNAs. We further extended our analysis of RNAa into rodent cell types.
We identified two saRNAs that induced the expression of mouse Cyclin B1 in NIH/3T3 and TRAMP C1 cells, which led to
increased phosphorylation of histone H3, a downstream marker for chromosome condensation and entry into mitosis. We
also identified two saRNAs that activated the expression of CXCR4 in primary rat adipose–derived stem cells.
Conclusions/Significance: This study demonstrates that RNAa exists in mammalian species other than human. Our findings
also suggest that nonhuman primate disease models may have clinical applicability for validating RNAa-based drugs.
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Introduction
RNAactivation (RNAa)isa newlydiscovered mechanism ofgene
activation directed by small double-stranded RNAs (dsRNAs) [1,2,3].
These dsRNAs, termed ‘small activating RNAs’ (saRNAs), exert an
effect opposite to that of RNA-interference (RNAi). Several models
of RNAa have been reported or proposed including transcriptional
activation by targeting promoter-specific sequences [1,3,4,5] and/
or gene antisense transcripts [6,7] leading to changes in chromatin
structure at the targeted gene. Small RNAs have also been shown to
enhance post-transcriptional gene expression by directly promoting
translation [8] or antagonizing miRNA target recognition [9].
Takentogether,therearelikelymultiplemechanisms inwhich small
RNAs can mediate gene induction. Regardless, what is becoming
clear is that RNAa has potential to be exploited to induce the
expression of a variety of genes in human cells.
RNAa is generally potent and long-lasting [1,2] making it a
promising therapeutic strategy for diseases that can be corrected
by stimulating gene expression. Ideally, RNAa can be applied as a
cancer treatment to re-activate tumor suppressor or pro-apoptotic
genes that are otherwise not targetable by current therapeutic
strategies. Although small animals such as mice and rats are
frequently used to test small molecule drugs, they may not be
suitable for testing RNA-based therapies. Because human and
rodent genetic sequences can diverge, a functional small RNA in
rodents may not be valid in humans, especially for those that target
gene promoter sequences. In contrast, non-human primates share
almost identical genome sequences with human and are more
ideal for testing genetic therapies. In fact, non-human primate
disease models are often used to test preclinical safety and efficacy
of vector-based gene therapy [10] and for testing systematic
delivery of RNAi-based therapeutics [11,12,13].
So far, RNAa has only been demonstrated in human cells and is
unknown whether it is conserved in other mammals. In the present
study, we replicate and identify new examples of RNAa in non-human
primate, mouse, and rat cells. We show that saRNAs derived from
human sequences have RNAa activity in non-human primate cells.
This suggests non-human primate disease models may have clinical
relevance in validating RNAa-based drugs. We also demonstrate
RNAa in other mammalian species by testing saRNAs derived from
mouse and rat sequence in rodent cells. Our findings reveal that
RNAa is prevalent in mammalian species other than human with
most of the genes tested being readily activated by saRNAs.
Results
We previously identified saRNAs that activated that expression
of E-cadherin, p21, and VEGF in human cells [1]. Sequence
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intended targeted sites for each human saRNA in primates (e.g.
Chimpanzee, Orangutan, and Rhesus monkey) were all highly-
conserved with human (data not shown). Conservation was
confirmed by sequencing DNA amplified from non-human
primate COS1 (African green monkey, AGM) and WES
(chimpanzee) cell lines (Fig. 1, GenBank accession numbers for
the resulted sequences are listed in Materials and Methods). Our
results also revealed subtle species-specific variations in sequence
between human, AGM, and chimpanzee excluding the possibility
Figure 1. Primate saRNA sequences and target alignments. Genomic DNA was isolated from WES and COS1 cells. Gene promoter regions
surrounding saRNA target sites were sequenced using promoter-specific primers. Indicated are the saRNA sequences aligned to human, Pan
troglodytes (PT; chimpanzee), and Cercopithecus aethiops (CA; African green monkey) promoter sequences. Target sites are highlighted in yellow,
while non-target sequence is highlighted in blue. Genomic sequences divergent from human are not highlighted. The numerical designation within
the name of each saRNA denotes the target location on each gene promoter relative to the transcription start site of the human gene.
doi:10.1371/journal.pone.0008848.g001
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human cells (Fig. 1). In order to replicate the phenomenon of
RNAa in non-human primate cells, we transfected both cell lines
with human saRNA targeting the E-cadherin promoter at position
2215 (dsEcad-215) or p21 promoter at position 2322 (dsP21–
322) relative to the transcription start sites (TSS). Compared to
control treatments, dsEcad-215 and dsP21–322 caused a ,1.6-
(p,0.05) and ,3.7-fold (p,0.05) increase in E-cadherin and p21
expression levels, respectively, in both cell lines (Fig. 2A and B).
Similar to what we observed in human cells [1], activation of
either E-cadherin or p21 in COS1 and WES cells significantly
inhibited cell proliferation and survival reflecting their roles as
tumor suppressor genes (Fig. S1). We also tested previously
identified human VEGF saRNA dsVEGF-706 and newly designed
dsVEGF-359 in both primate cell lines. In WES cells, dsVEGF-
359 and dsVEGF-706 induced VEGF mRNA expression by ,3.0-
(p=0.2) and ,5.3-fold (p,0.05), respectively (Fig. 2C). In COS1
cells, dsVEGF-706 significantly induced VEGF mRNA expression
by ,2-fold (p,0.01, Fig. 2C). ELISA confirmed that the secreted
form of VEGF (VEGF165) was induced following saRNA
treatment (Fig. S2).
To expand the list of known RNAa-responsive genes in primate
cells, we used a set of design rules (Materials and Methods) to
select saRNA targets for the following clinically relevant genes:
p53, PAR4, WT1, RB1, p27, NKX3-1, VDR, IL2, and pS2.
Genome sequence alignment revealed that these saRNA target
sites are well conserved between human and primates (Fig. 1 and
data not shown). Of the nine genes, p53, PAR4, WT1 and NKX3-
1 were induced $1.5-fold by their corresponding saRNA in at
least one of the two non-human primate cell lines (Fig. 2D–G).
To activate NKX3-1 expression, two saRNAs were designed
that targeted the human NKX3-1 promoter at positions 2360
(dsNKX3-1-360) and 2381 (dsNKX3-1-381) relative to the TSS.
The human dsNKX3-1-381 target sequence perfectly matched
those in the NKX3-1 promoter of chimpanzee and AGM, while
the dsNKX3-1-360 target site shared 94.7% and 84.2% sequence
identity with its cognates in chimpanzee and AGM, respectively
(Fig. 1). Compared to controls, dsNKX3-1-381 robustly induced
NKX3-1 mRNA expression in both WES (,3.5-fold, p,0.05) and
COS1 (,5.7-fold, p,0.01) cells (Fig. 2G), as well as displayed
altered morphology and decreased cell density characteristic of the
predicted tumor suppressor function of NKX3-1 [14] (Fig. S3).
Interestingly, despite having non-perfect homology, dsNKX3-1-
360 was still capable of inducing NKX3-1 mRNA expression by
,2-fold in both cell lines (Fig. 2G, p,0.05). To evaluate the
specificity of the saRNA (i.e. whether improved sequence
complementarity would enhance RNAa activity), we designed
species-specific NKX3-1 saRNAs that perfectly matched their
respective chimpanzee (dsNKX3-1-360-PT) and AGM (dsNKX3-
1-360-CA) targeted sequences. Both species-specific saRNAs were
found to have stronger RNAa activity compared to human
dsNKX3-1-360; NKX3-1 mRNA expression was increased by
Figure 2. RNA activation of different genes in non-human primate cells. A–G. COS1 and WES cells were transfected with 25 nM of the
indicated saRNAs for 3–5 days. Mock samples were transfected in the absence of saRNA. mRNA expression levels were analyzed by real-time PCR and
normalized to b-actin. Expression levels were measured as fold induction relative to mock transfections. The results are represented as mean 6 SEM
of three independent experiments. Species-specific saRNAs were designed to perfectly complement their respective chimpanzee (dsNKX3-1-360-PT)
and AGM (dsNKX3-1-360-CA) targeted sequences in WES and COS1 cells, respectively. Statistical significance is indicated (* p,0.05, ** p,0.01) as
compared to mock treatments.
doi:10.1371/journal.pone.0008848.g002
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(p,0.01, Fig. 2G). These results suggest that NKX3-1 activation is
sequence-dependent and RNAa in non-human primates can
tolerate mismatches in a manner analogous to microRNA target
recognition.
The p53 saRNA targeted sequence position 2285 (dsP53–285)
relative to the TSS in the human p53 promoter. The 2285 site is
comprised of a repetitive region unique to the p53 promoter that is
almost identical amongst human, chimpanzee, and AGM (Fig. 1).
In WES cells, activation of p53 by dsP53–285 resulted in PARP
cleavage indicative of caspase-dependent apoptosis; a consequence
of p53 overexpression [15] (Fig. 3A). To evaluate cell cycle
distribution, DNA content was analyzed by flow cytometry in cells
stained with propidium iodide. Transfection of dsP53–285 caused
a significant increase in G1/G0 and G2/M populations with a
concurrent decline in S populations as compared to control
treatments (Fig. 3B). Cell cycle arrest is associated with p53
induction and activation of downstream cell cycle inhibitory
protein p21 [16]. Consistent with this observation, p21 was also
induced by over 10-fold in dsP53-285-transfected cells (Fig. 3C).
We further extended our analysis of RNAa into mouse cells by
selecting Cyclin B1 (Ccnb1) as a candidate gene. Using the same
design rules, five saRNA targets were chosen on the mouse Ccnb1
promoter between 21200 to 2270 bp relative to the TSS
(Fig. 4A). We transfected the corresponding saRNAs into NIH/
3T3 and transgenic adenocarcinoma mouse prostate (TRAMP)
C1 cells and identified two saRNAs (dsCcnb1–313 and dsCcnb1–
597) that elevated Ccnb1 mRNA expression levels. In NIH/3T3
cells, dsCcnb1–313 and dsCcnb1–597 induced Ccnb1 levels by
,5.5- (p,0.01) and ,3.3-fold (p,0.05), respectively; whereas
dsCcnb1–597 induced Ccnb1 levels by ,3.2-fold (p,0.05) in
TRAMP C1 cells (Fig. 4B). Because Ccnb1 promotes entry into
mitosis, induction of Ccnb1 by dsCcnb1–313 or dsCcnb1–597 also
increased the phosphorylation of histone H3 at serine 10 (p-
H3S10) correlating with chromosome condensation during mitosis
[17] (Fig. 4C).
To explore RNAa in rat cells, we designed five saRNAs
targeting sequences between 2500 and 2250 bp relative to the
TSS in the promoter of rat chemokine receptor CXCR4 (Fig. 5A).
Primary rat adipose-derived stem cells (rADSCs) were transfected
with each duplex and CXCR4 expression levels were evaluated by
RT-PCR. Remarkably, two saRNAs (dsCXCR4–359 and
dsCXCR4–438) were identified that activated CXCR4 expression
(Fig. 5B). Compared to control treatments, dsCXCR4–359 and
dsCXCR4–438 both induced CXCR4 levels by ,2.5-fold in
rADSCs (Fig. 5C).
Discussion
RNA activation (RNAa) is a newly discovered mechanism of
small RNA-directed gene activation originally identified in human
cell lines [1,2,3]. It offers similar benefits as RNAi by utilizing
small dsRNAs, while representing a new method for gene
overexpression. As the momentum of RNAa increases within the
Figure 3. Activation of p53 by saRNA causes cell cycle arrest and induction of p21 in WES cells. A. WES cells were transfected with 25 nM
of the indicated saRNAs for 5 days. Protein levels of p53, PARP and p21 were detected by immunoblot analysis. b-actin served as a loading control. B.
WES cells were transfected as in A. Cells were collected, stained with propidium iodide, and processed for analysis by flow cytometry to measure DNA
content. Shown are examples of resulting FL2A histograms following analysis with FlowJo software. Cell populations distributed in G0/G1, S, and G2/
M phases of the cell cycle are indicated. C. WES cells were transfected with 25 nM of the indicated saRNAs for 72 hrs. p21 mRNA expression was
analyzed by real-time PCR. The results represent mean 6 SEM of two independent experiments and are plotted as fold induction relative to mock
transfections.
doi:10.1371/journal.pone.0008848.g003
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phenomenon is conserved in other mammalian species. Within
this study, we replicate and identify new examples of RNAa in
non-human primates, mouse, and rat cells. This not only
demonstrates conservation of RNAa, but also reveals its potential
application in animal studies other than human. In fact, during the
preparation of this manuscript, it was shown that lentiviral-based
delivery of shRNAs could activate VEGF expression by targeting
promoter sequences in an ischemic mouse model [18]. Further-
more, our findings suggest that non-human primate disease
models may have clinical application for validating RNAa-based
therapeutics. Because primates share almost identical genome
sequences with human, functional saRNAs may be conserved with
equal efficacy between non-human primates and humans.
RNAa offers a promising new therapeutic strategy for disease
that can be corrected by stimulating gene expression. Most of the
genes targeted within this study have clinical relevance in
regulating tumor cell growth. For instance, restoration of p53
function has recently been shown to cause dramatic tumor
regression in mice [19,20,21]. As such, the feasibility of activating
p53 by RNAa may have implications in cancer treatment.
Similarly, the tumor suppressive function of NKX3-1 in prostate
cancer may also offer a RNAa-based target for prostate cancer
therapy.
Application of RNAa is not limited to cancer therapeutics. It has
potential to serve as a substitute for vector-based overexpression in
a variety of systems. For instance, we demonstrate activation of
CXCR4 in primary rADSCs. CXCR4 plays an important role in
migration, engraftment, and proliferation of stem cells [22,23,24].
As such, RNAa may be useful in promoting stem cell phenotype
by targeting genes involved in reprogramming. Furthermore,
activation of CXCR in primary rat cells suggests RNAa has
relevant use in primary cell systems, as well.
Design of saRNAs has largely been a hit-or-miss process due to
a lack of complete understanding of the mechanism(s) and the
heterogeneous nature of different target regions with regard to
their impact on gene transcription. However, our design rules have
been met with some success. In the case of mouse Ccnb1 and rat
CXCR4, 2 out of the 5 saRNAs tested were capable of activating
target gene expression. Similarly, 4 out of the 9 genes screened in
non-human primate cells were found to be susceptible to RNAa in
at least one cell line. For the five genes we failed to activate by
RNAa (i.e. RB1, p27, VDR, IL2, and pS2), only one saRNA was
tested for each promoter. If more targets were screened, it may be
Figure 4. Ccnb1 activation in mouse cells by promoter-
targeting saRNAs. A. A schematic representation of the mouse
Ccnb1 promoter. Indicated is the transcription start site (+1) and
locations of the target sites for each putative saRNA. B. saRNAs were
transfected into mouse NIH/3T3 and TRAMP C1 cells at 50 nM
concentrations for 5 days. Ccnb1 mRNA levels were determined by
real-time RT-PCR and normalized to b-actin levels. Results are mean 6
SEM of 3 independent experiments. Statistical significance is indicated
(* p,0.05, ** p,0.01) as compared to mock treatments. C. NIH/3T3 and
TRAMP C1 cells were transfected as in B. Levels of Ccnb1 protein and
phospho-histone H3 at serine 10 (p-H3S10) were determined by
immunoblot analysis. Representative immunoblots are shown from 3
independent experiments.
doi:10.1371/journal.pone.0008848.g004
Figure 5. RNAa-mediated induction of CXCR4 in primary rat stem cells. A. A schematic representation of the rat CXCR4 promoter. Indicated
are the CpG islands, transcription start site (+1), and locations of the target sites corresponding to each of the five putative saRNAs. B. Each saRNA
was transfected at 50 nM concentrations into rADSCs for 4 days. CXCR4 and b-actin mRNA expression levels were assessed by standard RT-PCR. b-
actin served as a loading control. C. Expression of CXCR4 was quantified by densitometry and adjusted to b-actin levels. Results are mean 6 SEM of 3
independent experiments.
doi:10.1371/journal.pone.0008848.g005
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it is important to note that not all genes may be susceptible to
RNAa. For instance, genes silenced by DNA methylation may
confer resistance to RNAa [1]. For this reason, basal expression
was evaluated to confirm that the targeted genes were not
completely silenced. Regardless, RNAa offers a new approach to
enhance endogenous gene expression, which may be manipulated
to target a variety of genes. As such, RNAa has potential to
function as a surrogate tool for vector-based gene overexpression
systems.
Materials and Methods
Cell Culture and Transfection
African green monkey (Cercopithecus aethiops) COS1 kidney
fibroblast-like cells, Chimpanzee (Pan troglodytes) skin fibroblast
cells (WES), mouse NIH/3T3 cells were obtained from American
Type Culture Collection (Rockville, MD) and the UCSF Cell
Culture Facility. TRAMP C1 cells were kindly provided by Dr.
Marcella Fasso with permission from Dr. Norman Greenberg.
COS1 and WES cells were grown in Dulbecco’s Modified Eagle’s
Medium with 10% (v/v) fetal bovine serum (FBS), 100 U/ml
penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine.
NIH/3T3 cells were grown in Dulbecco’s Modified Eagle’s
Medium with 10% (v/v) bovine calf serum, 100 U/ml penicillin,
100 mg/ml streptomycin, and 2 mM L-glutamine. TRAMP C1
cells were grown as previously described [25]. Immediately before
transfection, cells were trypsinized, diluted with growth medium
without antibiotics, and seeded in 6-well plates (,2.5610
5 cells for
COS1 and WES cells and ,3610
4 cells for NIH/3T3 and
TRAMP C1 cells). Transfection of saRNA was carried out using
Lipofectamine RNAiMax or 2000 (Invitrogen, Carlsbad, CA)
according to the reverse transfection protocol provided with the
product. The cells were harvested 3–5 days following transfection
for analysis.
Rat Adipose–Derived Stem Cell (rADSC) Isolation and
Culture
Isolation and culture of rADSCs were performed as previously
described [26]. Briefly, rat adipose tissue was rinsed with PBS
containing 1% antibiotics, minced into small pieces, and incubated
in a solution of 0.075% collagenase Type IA (Sigma-Aldrich, St.
Louis, MO) for 1 h at 37uC. The upper insoluble lipid layer was
removed and the remaining liquid was centrifuged at 2006g for
10 min at room temperature. The pellet containing rADSCs was
treated with 160 mM NH4Cl for 10 minutes to lyse red blood cells.
The remaining cells were suspended in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v) FBS and
plated at a density of 1610
6 cells in 10 cm dishes. After reaching
,80% confluence, cells were split and cultured in DMEM
supplemented with 10% (v/v) FBS, 1% nonessential amino acid,
100 U/ml penicillin, 100 mg/ml streptomycin, 0.025 mg/ml
fungizone, and 110 mg/ml sodium pyruvate.
dsRNA Design
Promoter sequencesfor all primates were retrieved fromEnsembl
genome databases (www.ensembl.org) and analyzed against several
genome and sequence databases including dbTSS (Database of
Transcriptional Start Sites, http://dbtss.hgc.jp), AceView (http://
www.ncbi.nlm.nih.gov/IEB/Research/Acembly) and UCSC Ge-
nome Browser (http://genome.ucsc.edu) to determine transcription
start sites. Sequence alignments among all primates were provided
by the Ensembl database. Human promoter sequences were used as
the standard for saRNA design in non-human primates. Promoter
sequence was inputted into an Excel macro template that
implemented saRNA design rules derived from our previous and
on-going studies [1,3]. Based on these rules, the program assigned
weighted scores to all possible targets and returned a list of targets
sorted by sum scores. All tested saRNAs are listed in Table S1.
Design rules are listed below.
1. Targets were picked on the sense DNA sequence.
2. The RNA strand complementary to the sense DNA strand was
determined to be the guide strand; thus, the 39 end of the DNA
target corresponded to the 59 end of the guide RNA strand.
3. saRNA targets were selected in a region between approxi-
mately 21200 bp to 2200 bp upstream of transcription start
sites.
4. The size of each target is 19 nt. The resulting saRNA duplexes
possessed either dTdT or UU overhangs at the 39 end of each
strand.
5. Targets had a GC content of ,40–65%.
6. Consecutive nucleotides .4 were avoided.
7. The 39 end of a target possessed a lower thermodynamic
stability than its 59 end.
8. The 19th position was an ‘‘A’’.
9. The 18th position was an ‘‘A’’ or ‘‘T’’, preferably ‘‘A’’.
10. The 7th position was preferably a ‘‘T’’.
11. The 20th–23rd positions (flanking the 39 end of a target) were
preferably ‘‘A’’s or ‘‘T’’s
12. Sites susceptible to DNA methylation such as CpG islands,
CpG sites, and GC-rich regions were avoided because DNA
methylation was previously shown to interfere with RNAa
activity [1].
Promoter DNA Sequencing
DNA was extracted from COS1 and WES cells. Primers
complementary to genomic sequence (Table S1) were used to
amplify regions surrounding saRNA targeted sites in gene
promoters. PCR products were purified using a DNA clean-up
kit (Zymo Research, Orange, CA) and sequenced in both
directions. The resulted DNA sequences were deposited in
GenBank with the following accession numbers: GQ982508,
GQ982509, GQ982510, GQ982511, GQ982512, GQ982513,
GQ982514, GQ982515, GQ982516, GQ982517, GQ982518,
GQ982519, GQ982520, and GQ982521.
RNA Isolation and Analysis of Gene Expression
RNA from rADSCs was isolated by using the High pure RNA
isolation Kit (Roche, Indianapolis, IN). RNA from all other cell
lines was isolated by using the RNeasy Mini Kit (Qiagen,
Valencia, CA). Each RNA sample was treated with RNase-free
DNase I (Qiagen) to remove any potential contaminating DNA.
One microgram of RNA was used for cDNA synthesis using
oligo(dT)15–18 primers and M-MLV reverse transcriptase (Pro-
mega, Madison, WI). Real-time PCR was performed to quantify
gene expression by using gene-specific primer sets in conjunction
with Power SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA). Semi-quantitative RT-PCR was utilized to
evaluate rat CXCR4 and b-actin expression. PCR primer
sequences are listed in Table S1.
ELISA Analysis
Cells were transfected with 25 nM VEGF saRNA (dsVEGF-358
or dsVEGF-706) for 72 h. Culture media was then collected and
RNAa in Mammalian Cells
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concentration of secreted VEGF in the tissue culture media was
quantified by using the Quantikine Human VEGF Immunoassay
ELISA kit (R&D Systems, Minneapolis, MN) according to the
manufacturer’s instructions. VEGF concentrations were normal-
ized to the number of viable cells in each treatment.
Immunoblot Analysis
Cells were washed with PBS and lysed in RIPA buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycho-
late, 0.1% SDS) with protease and phosphatase inhibitor cocktail
for 15 min at 4uC. Lysates were clarified by centrifugation and
supernatants were collected. Protein concentration was deter-
mined by using a BCA protein assay kit (Thermo Scientific,
Waltham, MA). Proteins were resolved on SDS-PAGE gels and
transferred to nitrocellulose membranes. The resulting blots were
blocked with 5% non-fat dry milk and specific proteins were
detected with primary antibodies. Blots were subsequently
incubated with appropriate HRP-conjugated secondary antibodies
and antigen–antibody complexes were visualized by chemilumi-
nescence (Thermo Scientific). Primary antibodies used to detect
p53, Ccnb1, PARP, and b-actin protein levels included mouse
monoclonal anti-p53 (DO1; CalBiochem, San Diego, CA) at
1:5000, mouse monoclonal anti-Ccnb1 (V152; Cell signaling) at
1:1000, rabbit polyclonal anti-PARP (Cell Signaling, Danvers,
MA) at 1:1000, and mouse monoclonal anti-b-actin (Clone AC-15;
Sigma) at 1:3000. Phosphorylation of histone H3 at serine 10 was
detected by a rabbit polyclonal anti-phospho-histone H3 (ser10)
(Cell Signaling) at 1:500.
Clonogenic Survival Assay
Exponentially growing cells were seeded in 12-well plates and
reverse transfected with 25 nM saRNA using Lipofectamine
RNAiMax. After 24 hrs, the transfected cells were harvested and
seeded in 6-well plates at a density of 2000 cells/well. Culture
medium without antibiotics was changed every 3 days. Colony
formation was analyzed at day 12 by staining cells with crystal
violet.
Analysis of DNA Content by Flow Cytometry
saRNA transfected cells (1610
6 cells/ml) were trypsinized and
centrifuged at 25006ga t4 uC for 5 min and washed twice in PBS
buffer. The pellet was gently resuspended in 200 ml of PBS. The
resuspended cells were fixed with 5 ml of 70% cold (220uC)
ethanol on ice for 2 hrs. Before flow cytometry analysis, cells were
washed twice with cold PBS, resuspended in 1 ml of propidium
iodide (PI) staining solution (50 mg/ml PI, 10 mg/ml RNAse A,
0.1% Triton X-100, and 0.1% sodium citrate in PBS), and set at
room temperature for 30 min. The stained cells were analyzed on
a FACSCalibur flow cytometer for relative DNA content. The
resulting data was evaluated using the FlowJo software (Tree Star,
Inc., Ashland, OR).
Statistic Analysis of Gene Expression Data
mRNA expression quantification data was analyzed by one-way
analysis of variance (ANOVA) followed by Fisher’s exact test. A p-
value less than 0.05 was considered statistically significant.
Supporting Information
Table S1 Sequences for dsRNAs and oligonucleotide primers.
Found at: doi:10.1371/journal.pone.0008848.s001 (0.02 MB
PDF)
Figure S1 Induction of E-cadherin and p21 by RNAa inhibits
colony formation of COS1 and WES cells. COS1 and WES cells
were transfected with 25 nM of the indicated saRNAs. Mock
treatments were transfected in the absence of saRNA. One day
after transfection, cells were seeded in 6-well plates at a density of
2,000 cells/well. Colony formation was analyzed at day 12 by
staining the cells with crystal violet.
Found at: doi:10.1371/journal.pone.0008848.s002 (0.12 MB JPG)
Figure S2 VEGF saRNA transfection increases levels of secreted
VEGF. COS1 and WES cells were seeded in 12-well plates and
transfected at with 25 nM concentrations of saRNA. Culture
medium was collected and relative VEGF (VEGF165) concentra-
tions were determined by ELISA. VEGF concentrations are
shown as fold induction relative to mock treatments. Results are
presented as mean 6 SEM of two independent experiments.
Found at: doi:10.1371/journal.pone.0008848.s003 (0.12 MB JPG)
Figure S3 NKX3-1 saRNA inhibits COS1 and WES cell
growth. A. COS1 and WES cells were transfected with 25 nM
of the indicated dsRNAs for 96 hrs. Cell images were taken at
1006 magnification by phase contrast microscopy. Note:
dsNKX3-1-381 transfected cells appear less dense and have
acquired narrower, elongated shapes compared to control
treatments. B. Cell density was quantified by counting the number
of attached cells from five randomly selected fields as viewed under
an inverted microscope at 1006 magnification. Cell density and
statistical significance (** p,0.001) is shown relative to mock
transfections.
Found at: doi:10.1371/journal.pone.0008848.s004 (0.78 MB JPG)
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